Biocompatibility of icodextrin.

Peritoneal dialysis (PD) has been a successful form of As a result of the growing awareness of the potential chronic renal replacement therapy for more than twenty effects of glucose-based solutions on membrane physiolyears. In spite of the successes of this therapy, there is ogy, there has been an increased emphasis on the devela growing awareness that the high glucose content of PD opment of second-generation PD solutions that reduce solutions may ultimately compromise membrane perforor eliminate glucose exposure and are more biocompatimance over time, a realization that underlies the search ble with membrane biological and metabolic processes for, and production of, glucose-free solutions. Icodextrin, [30–34]. one of the second-generation PD solutions, was develThe biocompatibility of a PD solution can be defined oped as an alternative to glucose-based solutions to proas the ability of a solution formulation to permit longvide a sustained level of ultrafiltration through the use term dialysis without any clinically significant changes of a glucose polymer as the osmotic agent, and is curin the functional characteristics of the peritoneum and, rently used by more than 9000 patients worldwide. While as such, is of paramount importance not only in mainicodextrin has now proven itself to be clinically useful taining the health of the membrane, but also in permitin the fluid management of PD patients, there are indicating PD to be a successful long-term therapy. The potentions that it also may demonstrate improved biocompatitial role of PD solution biocompatible factors in clinical bility when compared to the traditional solutions. This outcomes is illustrated in Figure 1. Solution components review evaluates the biocompatibility of icodextrin vercan affect leukocyte, mesothelial cell, endothelial cell, and sus glucose-based solutions, and shows how this new fibroblast function, resulting in alterations in cytokine, solution may significantly contribute to an overall therachemokine, and growth factor networks, up-regulation peutic strategy for improving PD. of pro-inflammatory and profibrotic pathways, impaired peritoneal host defense, and the induction of carbonyl and oxidative stress. Such perturbations of normal physiBIOCOMPATIBILITY ology have been proposed as causative factors contributThe peritoneal membrane is a complex tissue that ing to changes in peritoneal structure, such as peritoneal plays a pivotal role in peritoneal cavity homeostasis [1]. fibrosis, sclerosis and vasculopathy, and changes in periThe cellular components of the membrane are active toneal function, including increased solute permeability in host defense [2–5], maintain a balance of peritoneal and ultrafiltration (UF) failure. coagulant and fibrinolytic activity [6–9], contribute to The characteristics of conventional glucose-based dialmembrane repair and remodeling of the extracellular ysis solutions that have been reported to affect the biomatrix [10, 11], and regulate cytokine and chemokine compatibility of the formulation include the pH/buffer production (Table 1) (abstract; Jorres et al, Nephrol Dial system, the osmolarity, the glucose concentration, and Transplant 8:1023, 1993) [12–15]. The membrane itself the glucose degradation product (GDP) profile of that functions as a semipermeable barrier regulating the sesolution. Icodextrin is virtually identical to glucose-based lective transport of water and solutes between the sysPD solutions in its formulation except for the replacetemic circulation and the peritoneal cavity during PD. ment of glucose with icodextrin as the osmotic agent It is becoming increasingly apparent that, in spite of the (Table 2). Icodextrin is a high molecular weight glucose success of PD as a renal replacement therapy, chronic polymer fraction of hydrolyzed corn starch. Briefly, it is exposure to glucose-based solutions may compromise a mixture of d-glucopyranose polymers of different chain the biological function of the peritoneal membrane [28, 29]. lengths, between 4 and 250 units, linked by -(1-4) and -(1-6) glucosidic bonds, exhibiting a mean molecular weight of 16,200 Daltons (D). The chemical properties

[1]  O. Devuyst,et al.  Toward better dialysis compatibility: advances in the biochemistry and pathophysiology of the peritoneal membranes. , 2002, Kidney international.

[2]  Geraint T. Williams,et al.  Morphologic changes in the peritoneal membrane of patients with renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[3]  J. Wautier,et al.  AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. , 2002, Kidney international.

[4]  M. Kolb,et al.  Gene Transfer of Transforming Growth Factor- 1 to the Rat Peritoneum: Effects on Membrane Function , 2001 .

[5]  S. B. Kim,et al.  High glucose induces MCP-1 expression partly via tyrosine kinase-AP-1 pathway in peritoneal mesothelial cells. , 2001, Kidney international.

[6]  W. Reichel,et al.  A Case of Sterile Peritonitis Associated with Icodextrin Solution , 2001, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[7]  P. Heering,et al.  Peritoneal Reaction to Icodextrin in a Female Patient on CAPD , 2001, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[8]  K. Lai,et al.  Expression of aquaporin-1 in human peritoneal mesothelial cells and its upregulation by glucose in vitro. , 2001, Journal of the American Society of Nephrology : JASN.

[9]  R. Krediet,et al.  Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. , 2001, Kidney international.

[10]  A. Douvdevani,et al.  CD40 is expressed on human peritoneal mesothelial cells and upregulates the production of interleukin-15 and RANTES. , 2001, Journal of the American Society of Nephrology : JASN.

[11]  D. Marples Aquaporins: Roles in Renal Function and Peritoneal Dialysis , 2001, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[12]  U. Frei,et al.  Glucose Degradation Products and Peritoneal Membrane Function , 2001, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[13]  H. Ha,et al.  High glucose–induced PKC activation mediates TGF-β1 and fibronectin synthesis by peritoneal mesothelial cells , 2001 .

[14]  A. Donker,et al.  Amadori Albumin and Advanced Glycation End-Product Formation in Peritoneal Dialysis using Icodextrin , 2001, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[15]  M. Ishida,et al.  Hyperosmotic stimuli induces recruitment of aquaporin-1 to plasma membrane in cultured rat peritoneal mesothelial cells. , 2001, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[16]  H. Kang,et al.  Effects of Conventional and New Peritoneal Dialysis Solutions on Human Peritoneal Mesothelial Cell Viability and Proliferation , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[17]  T. Miyata,et al.  Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluids. , 2000, Kidney international.

[18]  P. Stenvinkel,et al.  Biocompatibility of New Peritoneal Dialysis Solutions: What Can We Hope to Achieve? , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[19]  L. Gotloib,et al.  High glucose accelerates the life cycle of the in vivo exposed mesothelium. , 2000, Kidney international.

[20]  R. Selgas,et al.  Icodextrin Effluent Leads to a Greater Proliferation than Glucose Effluent of Human Mesothelial Cells Studied Ex Vivo , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[21]  K. Nolph,et al.  Advanced Glycosylation End-Products in Diabetic Rats on Peritoneal Dialysis Using Various Solutions , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[22]  N. Yorioka,et al.  Effect of glucose on intercellular junctions of cultured human peritoneal mesothelial cells. , 2000, Journal of the American Society of Nephrology : JASN.

[23]  R. Gokal Newer peritoneal dialysis solutions. , 2000, Advances in renal replacement therapy.

[24]  M. Davies,et al.  Production and Regulation of Matrix Metalloproteinases and Their Inhibitors by Human Peritoneal Mesothelial Cells , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[25]  T. Miyata,et al.  Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds. , 2000, Kidney international.

[26]  M. Bonomini,et al.  A new form of acute adverse reaction to icodextrin in a peritoneal dialysis patient. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  L. Gotloib,et al.  Effects of Osmotic Agents upon the in Vivo Exposed Mesothelial Monolayer , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[28]  C. Holmes,et al.  Strategies to Reduce Glucose Exposure in Peritoneal Dialysis Patients , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[29]  O. Devuyst,et al.  Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. , 2000, Journal of the American Society of Nephrology : JASN.

[30]  U. Frei,et al.  Effect of glucose degradation products on human peritoneal mesothelial cell function. , 2000, Journal of the American Society of Nephrology : JASN.

[31]  A. Donker,et al.  Peritoneal Kinetics and Mesothelial Markers in CCPD Using Icodextrin for Daytime Dwell for Two Years , 2000, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[32]  T. Kooistra,et al.  D-glucose Increases the Synthesis of Tissue-type Plasminogen Activator (t-PA) in Human Peritoneal Mesothelial Cells , 1999, Thrombosis and Haemostasis.

[33]  G. D'Amico,et al.  Recurrent Sterile Peritonitis at Onset of Treatment with Icodextrin Solution , 1999, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[34]  A. Donker,et al.  Peritoneal Defense Using Icodextrin Or Glucose for Daytime Dwell in Ccpd Patients , 1999, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[35]  K. Nitta,et al.  Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[36]  W. Yang,et al.  Interleukin-1β Stimulates the Production of Extracellular Matrix in Cultured Human Peritoneal Mesothelial Cells , 1999 .

[37]  T. Tomo,et al.  Maillard Reaction and Age Formation in Glucose and Polyglucose Dialysis Solutions , 1999, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[38]  D. Kang,et al.  High Glucose Solution and Spent Dialysate Stimulate the Synthesis of Transforming Growth Factor-β1 of Human Peritoneal Mesothelial Cells: Effect of Cytokine Costimulation , 1999 .

[39]  T. Miyata,et al.  Carbonyl Stress: Increased Carbonyl Modification of Proteins by Autoxidation Products of Carbohydrates and Lipids in Uremia , 1999, The International journal of artificial organs.

[40]  P. Erhard,et al.  Analysis of Non Enzymatic Glycosylation In Vivo: Impact of Different Dialysis Solutions , 1999, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[41]  C van Ypersele de Strihou,et al.  Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. , 1999, Kidney international.

[42]  C. Holmes,et al.  Effect of icodextrin peritoneal dialysis solution on cell proliferation in vitro. , 1999, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[43]  R. Krediet The peritoneal membrane in chronic peritoneal dialysis. , 1999, Kidney international.

[44]  T. Kooistra,et al.  Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator. , 1999, Kidney international.

[45]  N. Yorioka,et al.  Advanced Glycation End-Products Reduce the Viability of Human Peritoneal Mesothelial Cells , 1998, Nephron.

[46]  S. Mandl,et al.  High glucose increases prostaglandin E2 synthesis in human peritoneal mesothelial cells: role of hyperosmolarity. , 1998, Journal of the American Society of Nephrology : JASN.

[47]  R. Vanholder,et al.  Consequences of Using Glucose in Peritoneal Dialysis Fluid , 1998 .

[48]  G. Sobue,et al.  Accelerated formation of N epsilon-(carboxymethyl) lysine, an advanced glycation end product, by glyoxal and 3-deoxyglucosone in cultured rat sensory neurons. , 1998, Biochemical and biophysical research communications.

[49]  B. Grabensee,et al.  Effect of alternative peritoneal dialysis solutions on cell viability, apoptosis/necrosis and cytokine expression in human monocytes. , 1998, Kidney international.

[50]  T. Henle,et al.  3-Deoxyglucosone, a Promoter of Advanced Glycation end Products in Fluids for Peritoneal Dialysis , 1998, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[51]  M. Kretzler,et al.  Expression of glucose transporters in human peritoneal mesothelial cells. , 1998, Kidney international.

[52]  R. Bucala,et al.  Advanced glycation end products increase retinal vascular endothelial growth factor expression. , 1998, The Journal of clinical investigation.

[53]  J. Moberly,et al.  New developments in peritoneal dialysis solutions. , 1998, Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

[54]  M. Davies,et al.  Response of the human peritoneal mesothelial cell to injury: an in vitro model of peritoneal wound healing. , 1998, Kidney international.

[55]  T. Watanabe,et al.  Advanced glycation endproducts stimulate mitogen-activated protein kinase and proliferation in rabbit vascular smooth muscle cells. , 1997, Biochemical and biophysical research communications.

[56]  J. Lin,et al.  Absence of Modulating Effects of Cytokines on Antioxidant Enzymes in Peritoneal Mesothelial Cells , 1997, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[57]  T. Mettang,et al.  In vitro effects of glucose polymer-containing peritoneal dialysis fluids on phagocytic activity. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[58]  D. Millar,et al.  Glycation and Advanced Glycation End-Product Formation with Icodextrin and Dextrose , 1997, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[59]  B. Risberg,et al.  Plasminogen activators and inhibitors in peritoneal tissue , 1997, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[60]  L. Henderson,et al.  Impact of terminal heat sterilization on the quality of peritoneal dialysis solutions. , 1997, Blood purification.

[61]  T. Shigematsu,et al.  Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. , 1997, Kidney international.

[62]  Nagy Ja Peritoneal membrane morphology and function. , 1996 .

[63]  T. Kooistra,et al.  Modulation of procoagulant and fibrinolytic system components of mesothelial cells by inflammatory mediators. , 1996, The American journal of physiology.

[64]  M. Davies,et al.  IL-1 beta, a major stimulator of hyaluronan synthesis in vitro of human peritoneal mesothelial cells: relevance to peritonitis in CAPD. , 1996, Kidney international.

[65]  N. Topley,et al.  Macrophages and mesothelial cells in bacterial peritonitis. , 1996, Immunobiology.

[66]  P. Klingler,et al.  Transforming growth factor-beta synthesis by human peritoneal mesothelial cells. Induction by interleukin-1. , 1996, The American journal of pathology.

[67]  W. Luttmann,et al.  Adherence of neutrophils to human peritoneal mesothelial cells: role of intercellular adhesion molecule-1. , 1996, Journal of the American Society of Nephrology : JASN.

[68]  A. Wieslander,et al.  Glucose Degradation and Cytotoxicity in Pd Fluids , 1996, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[69]  J. Hjelle,et al.  Effects of osmotic solutes on fibronectin mRNA expression in rat peritoneal mesothelial cells. , 1996, Blood purification.

[70]  G. Sozzi,et al.  Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement. , 1996, Cytogenetics and cell genetics.

[71]  K. Nitta,et al.  Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. , 1996, Nephron.

[72]  H. Verbrugh,et al.  First -Line Defense Mechanisms in the Peritoneal Cavity during Peritoneal Dialysis , 1995, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[73]  M. Shimoda,et al.  The Role of Tgf-β in Growth Inhibition of Peritoneal Mesothelial Cells in High-Glucose Dialysate , 1995, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[74]  A. Wieslander,et al.  Are Aldehydes in Heat-Sterllized Peritoneal Dialysis Fluids Toxic in Vitro? , 1995, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[75]  A. Dawnay,et al.  In vitro formation of advanced glycation end products in peritoneal dialysis fluid. , 1995, Kidney international.

[76]  N. Topley The Host's Initial Response to Peritoneal Infection: The Pivotal Role of the Mesothelial Cell , 1995, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[77]  E. Stylianou,et al.  Source of peritoneal proteoglycans. Human peritoneal mesothelial cells synthesize and secrete mainly small dermatan sulfate proteoglycans. , 1995, The American journal of pathology.

[78]  B. Holmquist,et al.  Development of Toxic Degradation Products during Heat Sterilization of Glucose-Containing Fluids for Peritoneal Dialysis: Influence of Time and Temperature , 1995, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[79]  Paul J Thornalley,et al.  Formation of methylglyoxal-modified proteins in vitro and in vivo and their involvement in AGE-related processes. , 1995, Contributions to nephrology.

[80]  C. Holmes Peritoneal host defense mechanisms in peritoneal dialysis. , 1994, Kidney international. Supplement.

[81]  S. Argov,et al.  Human peritoneal mesothelial cells synthesize IL-1α and β , 1994 .

[82]  M. Raftery,et al.  A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. , 1994, Kidney international.

[83]  R. Clark,et al.  Enhanced body growth in uremic rats treated with IGF-I and growth hormone in combination. , 1994, Kidney international.

[84]  R. Alsop,et al.  History, Chemical, and Pharmaceutical Development of Icodextrin , 1994 .

[85]  H. Seo,et al.  Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. , 1994, The Journal of clinical investigation.

[86]  J. Dobbie Ultrastructure and pathology of the peritoneum in peritoneal dialysis , 1994 .

[87]  N. Topley,et al.  In-vitro biocompatibility of alternative CAPD fluids; comparison of bicarbonate-buffered and glucose-polymer-based solutions. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[88]  A. Wieslander,et al.  Heat Sterilization of Fluids for Peritoneal Dialysis Gives Rise to Aldehydes , 1993, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[89]  A. Wieslander,et al.  Heat sterilized PD-fluids impair growth and inflammatory responses of cultured cell lines and human leukocytes. , 1993, Clinical nephrology.

[90]  J. Westwick,et al.  Human peritoneal mesothelial cells synthesize interleukin-8. Synergistic induction by interleukin-1 beta and tumor necrosis factor-alpha. , 1993, The American journal of pathology.

[91]  A. Donker,et al.  Biocompatibility of a glucose-polymer-containing peritoneal dialysis fluid. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[92]  T. Liberek,et al.  Cell Function and Viability in Glucose Polymer Peritoneal Dialysis Fluids , 1993, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[93]  W. Luttmann,et al.  Human peritoneal mesothelial cells synthesize interleukin-6: Induction by IL-1β and TNFα , 1993 .

[94]  A. Wieslander,et al.  Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929. , 1991, Kidney international.

[95]  E. Stylianou,et al.  Isolation, culture and characterization of human peritoneal mesothelial cells. , 1990, Kidney international.

[96]  T. Kooistra,et al.  Characterization and fibrinolytic properties of human omental tissue mesothelial cells. Comparison with endothelial cells. , 1990, Blood.

[97]  Lloyd Jk,et al.  Categorization of ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients. , 1990 .

[98]  G. Sacchi,et al.  Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): an in vivo model for the study of diabetic microangiopathy. , 1989 .

[99]  R. Gokal,et al.  ULTRAFILTRATION WITH AN ISOSMOTIC SOLUTION DURING LONG PERITONEAL DIALYSIS EXCHANGES , 1987, The Lancet.

[100]  T. Strom,et al.  Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. , 1986, Journal of immunology.

[101]  P. Schollmeyer,et al.  Prostaglandin-mediated loss of proteins during peritonitis in continuous ambulatory peritoneal dialysis. , 1986, Kidney international.

[102]  E. Jenkins,et al.  Letter: Differential sister-chromatid staining. , 1975, Lancet.